SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
MARSHALL EDWARDS
(NASDAQ:MSHL Last Sale: .82 +.0499)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NASDAQ: (MSHL : $.82)
$60 million Market Cap at Market Close, September 2, 2010
Biomedics SubIndustry up .90% / Health Industry up .58% Today
140 Wicks Road Research Report Earnings Snapshot - Last 10/13/08
North Ryde, NSW, 2113 Annual Reports
Australia
Phone: (011) 61 2 8877- 6196

Christopher Naughton, CEO, David R. Seaton, CFO
Spin-off of Australia's NOVOGEN LTD. (NasdaqNM:NVGN). Developing a new family of anti-cancer drugs. IPO proceeds to be used for human clinical trials of phenoxodiol, its leading drug. IPO at $7.50 December 17, 2003. Raised $15.6 million, selling 2.1 million shares, 4% of the outstanding. Lead Manager: Janney Montgomery Scott.
Historical Charts    Technical Analysis

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common MSHL $.82 $.7701 .0499 6.5 $.77 $.82 600 $.47 $5.51 73,463
Warrants MSHLW $.02 $ 0 $.01 $.08 402,106 $ $ 0
Capitalization
Earnings Summary
*** No Earnings Available***
-10047
Common Stock $60,240

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2010 Stock Smart with all rights reserved
Quotes are delayed 15 minutes or more for Nasdaq, 20 minutes or more for NYSE/AMEX. Provided by TTI